HeartBeam to Host Virtual Roadshow Webinar on Tuesday September 20, 2022 at 4:30 p.m. Eastern Time
September 12 2022 - 8:31AM
Business Wire
Unveils New Video Featuring the HeartBeam AIMI™
and AIMIGo™ Technology
HeartBeam, Inc. (NASDAQ: BEAT), a developmental stage
digital healthcare company with a proprietary ECG telemedicine
technology for heart attack detection, today announced that it will
host a virtual roadshow webinar on Tuesday September 20, 2022, at
4:30 p.m. Eastern Time.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20220912005339/en/
(Graphic: Business Wire)
During the webinar, a new video showcasing the HeartBeam AIMIGo
platform technology for use in heart attack detection will be
unveiled. HeartBeam AIMI and AIMIGo have not yet been cleared by
the US Food and Drug Administration (FDA) for marketing in the USA
or other geographies.
The video is available in the company’s investor relations
section here.
The video takes viewers behind the scenes for a featured look at
the HeartBeam AIMIGo technology, a medical grade solution with a
510(K) regulatory pathway that the company expects to submit to FDA
for clearance by the end of the year. Once cleared, for the first
time outside of a medical setting, the Company believes that AIMIGo
can enable patients and their clinicians to determine if symptoms
are due to a heart attack, quickly and easily, so care can be
initiated, if needed. The goal of HeartBeam’s technology is to
offer more accurate heart attack detection to triage patients and
expedite treatment and save healthcare dollars.
HeartBeam’s CEO and founder Branislav Vajdic, PhD, CFO Rick
Brounstein, and Chief Business Officer Jon Hunt, PhD, will host the
virtual roadshow webinar, during which they will review recent
announcements, including its 510(k) application to the FDA for its
HeartBeam AIMI™ platform technology, ongoing initiatives and
discuss key 2022 and 2023 milestones. The webinar will be
accompanied by a presentation and followed by a question-and-answer
session from webcast viewers, which can be accessed via the webcast
link.
To access the webinar, please use the following information:
Date:
Tuesday September 20, 2022
Time:
4:30 p.m. Eastern time (1:30 p.m. Pacific
time)
Dial-in:
1-877-704-4453
International Dial-in:
1-201-389-0920
Conference Code:
13732771
Webcast:
https://viavid.webcasts.com/starthere.jsp?ei=1569585&tp_key=156ad0b0f4
A telephone replay will be available approximately two hours
after the call and will run through December 20, 2022, by dialing
1-844-512-2921 from the U.S., or 1-412-317-6671 from international
locations, and entering replay pin number: 13732771. The replay can
also be viewed through the webinar webcast link above and the
presentation utilized during the call will be available in the
company’s investor relations section here.
About HeartBeam, Inc.
HeartBeam, Inc. (NASDAQ: BEAT) is a development stage digital
healthcare company with proprietary ECG telemedicine technology
that will redefine the way high risk cardiovascular patients are
diagnosed in an ambulatory setting at any time and any place. Its
breakthrough solution employs a reusable, credit card sized, 3D
vector ECG recording device and cloud-based software capable of
assisting a physician in diagnosing a wide range of cardiovascular
disease. HeartBeam is initially focusing on a huge unmet need of
helping diagnose heart attacks in patients outside of a medical
institution. No single lead ECG technology can offer this value to
patients and their physicians. This underserved market is several
times larger than the cardiac arrhythmia detection market based on
the prevalence of patients with coronary artery disease at high
risk of heart attack. For more information, visit
www.heartbeam.com.
Forward-Looking Statements
All statements in this release that are not based on historical
fact are "forward-looking statements." While management has based
any forward-looking statements included in this release on its
current expectations, the information on which such expectations
were based may change. Forward-looking statements involve inherent
risks and uncertainties which could cause actual results to differ
materially from those in the forward-looking statements, as a
result of various factors including those risks and uncertainties
described in the Risk Factors and in Management’s Discussion and
Analysis of Financial Condition and Results of Operations sections
of our in our Forms 10-K, 10-Q and other reports filed with the SEC
and available at www.sec.gov. We urge you to consider those risks
and uncertainties in evaluating our forward-looking statements. We
caution readers not to place undue reliance upon any such
forward-looking statements, which speak only as of the date made.
Except as otherwise required by the federal securities laws, we
disclaim any obligation or undertaking to publicly release any
updates or revisions to any forward-looking statement contained
herein (or elsewhere) to reflect any change in our expectations
with regard thereto or any change in events, conditions or
circumstances on which any such statement is based.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220912005339/en/
Media and Investor Relations Contact: Chris Tyson
Executive Vice President MZ North America Direct: 949-491-8235
BEAT@mzgroup.us www.mzgroup.us
HeartBeam (NASDAQ:BEAT)
Historical Stock Chart
From Aug 2024 to Sep 2024
HeartBeam (NASDAQ:BEAT)
Historical Stock Chart
From Sep 2023 to Sep 2024